Rare Systemic Vasculitides: Polyarteritis Nodosa and Takayasu Arteritis
Abstract
BACKGROUND Polyarteritis nodosa (PAN) and Takayasu arteritis (TA) are systemic medium- and large-vessel vasculitides associated with significant morbidity when diagnosis is delayed. Although described in the literature, reports directly demonstrating the impact of diagnostic timing on vascular outcomes remain limited. This report presents 2 rare and contrasting cases highlighting the importance of early recognition with timely vascular and immunosuppressive interventions, which can prevent irreversible ischemic complications, whereas delayed diagnosis can result in permanent structural damage, reinforcing the need for accurate differentiation between PAN and TA. CASE REPORT Case 1 was a young woman with refractory hypertension and significant vascular manifestations, in whom PAN was diagnosed through combined analysis of symptoms, laboratory tests, and angiographic findings. Early angioplasty and treatment with glucocorticoids and azathioprine resulted in a favorable response. Case 2 was a woman with TA who had extensive involvement of the aorta and its branches with irreversible sequelae, including aortic valve replacement. Diagnostic delay led to progression. Glucocorticoids and adalimumab achieved clinical stabilization without reversing established structural damage. CONCLUSIONS The presented cases reinforce the importance of early identification and appropriate differentiation of systemic vasculitides to prevent irreversible vascular lesions. This study compares a case…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.